Donate

Publication Details

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Nivolumab (OPDIVO®) [Polish]

Nivolumab (OPDIVO®) [Polish] (January 2020)

Nivolumab (OPDIVO®) is a targeted therapy drug used to treat melanoma, non-small cell lung cancer or kidney (renal cell) cancer. 

Author(s)
Macmillan Cancer Support
Place of publication
London
Publisher
Macmillan Cancer Support
Date of publication
January 2020
Pages
12pp
Supplier
https://www.macmillan.org.uk/, https://be.macmillan.org.uk/be
Subject(s)
Nivolumab, OPDIVO®, Monoclonal antibodies, Lung cancer, non-small-cell, Kidney cancer, Malignant melanoma
Format
Factsheet
Language
Polish
Download this resource
Download this resource
Back to results
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Donate

About this site

Macmillan sites

Right there with you

We're here to provide physical, financial and emotional support. So whatever cancer throws your way, we're right there with you. Contact us

Follow us

© Macmillan Cancer Support 2019 © Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). Also operating in Northern Ireland. A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 89 Albert Embankment, London SE1 7UQ. VAT no: 668265007